Exesalibero Pharma, Inc.

Morgantown, WV Grants

UEI
HVMJC4FQ8RM7
CAGE
78MM6
Primary NAICS
325412 Pharmaceutical Preparation Manufacturing
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • Self Certified Small Disadvantaged Business
  • For Profit Organization
  • Subchapter S Corporation
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
3601 Monarch Ct, Morgantown, WV 26508, USA
Website
exesalibero-pharma.com
Employees
1-10
Estimated annual revenue
$0-$1M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
Development of the novel small-molecule anti-osteoclastic drug ELP-004 to alleviate the symptoms of osteogenesis… R43AR087150 National Insititue of Arthritis and Musculoskeletal and Skin Diseases (NIH) $172,164
Prevention of arthritis-induced bone erosion by inhibiting osteoclast differentiation by the haloanilide n-methyl… R42AR074812 National Insititue of Arthritis and Musculoskeletal and Skin Diseases (NIH) $2,498,828

Quick answers

Is Exesalibero Pharma, Inc. registered in SAM.gov?

Yes. Exesalibero Pharma, Inc.'s SAM.gov registration is active through July 14, 2027.

What is Exesalibero Pharma, Inc.'s most recent federal award?

Exesalibero Pharma, Inc.'s most recent federal grant award is Development of the novel small-molecule anti-osteoclastic drug ELP-004 to alleviate the symptoms of osteogenesis… (R43AR087150), from National Insititue of Arthritis and Musculoskeletal and Skin Diseases (NIH), on August 15, 2026.

On GovTribe

See Exesalibero Pharma, Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login